NCBiotech News

More than 150 people attending the Digital Health 360 Summit in Durham last month focused on three topics: identifying barriers to healthcare engagement, building healthy communities, and using digital technology to strengthen precision health in North Carolina.

Circassia Pharmaceuticals, a British company with U.S. headquarters in Morrisville, plans to acquire the full U.S. commercial rights to Tudorza, a treatment for chronic obstructive pulmonary disease (COPD) from British drug-maker AstraZeneca by the end of this month.

Due to the continuation of inclement weather, the NC Biotechnology Center RTP locatiion is closed for the remainder of the day,  Monday, December 10, 2018. 

Because of winter weather, NCBiotech offices have adjusted hours as follows:

• RTP's office will open at noon on Monday, December 10, 2018.
• Piedmont Triad office is closed Monday and Tuesday, working remotely.

Check back for additional updates.

Facility Logix, a Maryland-based consulting firm that helps bioscience companies with lab and biomanufacturing facilities, has opened a North Carolina office and hired a project manager to run it.

Bristol Myers Squibb is the latest pharmaceutical heavyweight to enter a strategic partnership with Chapel Hill’s TARGET PharmaSolutions to study a major disease.

Loans from the North Carolina Biotechnology Center totaling $1 million will help three bioscience companies develop novel products for better human health.

Criticality, a young company developing nutraceuticals from specialized North Carolina hemp plants, has launched its inaugural line of consumer cannabidiol (CBD) products, under the brand name Korent.

Research Triangle Park-based clinical-stage biopharmaceutical company G1 Therapeutics has reported more positive results for its investigational oncology drug, trilaciclib.

Precision BioSciences, a genome-editing company based in Durham, has received authorization from the U.S. Food and Drug Administration to begin a study of its first clinical-stage product candidate, a cancer immunotherapy.

Bioscience companies from North Carolina dominated the awards competition at the 20th annual SEBIO Investor and Partnering Forum in Atlanta this month, with nine Tar Heel firms earning recognition.

Fervent Pharmaceuticals of Greenville has finished a Phase 2A clinical trial of FP-101, its new therapy for treating symptoms of menopause including hot flashes and night sweats.

Perhaps the best way to know where food comes from, and where it’s been since its origin, is by using a fast-evolving technology-based system called blockchain. It’s a concept that enables tagging and tracking everything from food to fiber and beyond. And it’s going to rock our world.

Chapel Hill-based TARGET PharmaSolutions, a clinical data company focused on real-world evidence in disease studies, has formed a strategic partnership with Gilead Sciences to better understand two major liver disorders.

Cambrex Corp., a contract manufacturer of small-molecule therapeutics with a growing facility in High Point, has signed an agreement to acquire Avista Pharma Solutions, a contract development, manufacturing and testing organization (CDMO) in East Rutherford, N.J., for about $252 million.